G E O R G E T H E R A P O N D O S , M B C H B , F R C P C , M P H

T R A N S P L A N T H E P A T O L O G Y

O C H S N E R M U L T I O R G A N T R A N S P L A N T I N S T I T U T E

N E W O R L E A N S

Hepatocellular carcinomaNew developments

Disclosures

Advisory boards:

Boston Scientific

Mallinckrodt Pharma

Rebiotix Inc

Speaker’s bureau

Intercept Pharma

Eisai Co.= maker of Lenvatinib

Pembrolizumab

APPROVED!

Currently approved therapies

Only approved first line agents

Sorafenib

Lenvatinib

Regorafenib

Cabozantinib

Ramucirumab

Nivolumab

Multiple combination trials are ongooing

Durvalumab+ Tremelimumab

Nivolumab+ Ipilimumab/Cabozantinib

Lenvatinib+Pembrolizumab

Atezolizumab+ Bevacizumab

Nivolumab+ Sorafenib

Take home points

1) Rapidly evolving field

2) Choice of treatment for advanced HCC

TKIs

Immunotherapy

3)

First line= Sorafenib/Lenvatinib

Second line= multiple agents

Oncology involvement essential